每年專案
個人檔案
學歷
- 國防醫學院醫學院醫學士
經歷
- 2022.11- 臺北醫學大學癌症轉譯研究中心主任
- 2022.04- 泰福生技股份有限公司獨立董事
- 2020.11- Distinguished Investigator and Director of Institute of Biotechnology and Pharmaceutical Research, NHRI
- 2022.11-2024.01 臺北癌症中心院長
- 2020.08 Distinguished Investigator and Attending Physician of National Institute of Cancer Research, NHRI
- 2020.08 Professor Emeritus, National Cheng Kung University
- 2019.02-2020.07 Executive Vice President, National Cheng Kung University
- 2019.02-2020.07 Director of University Center for Bioscience and biotechnology, NCKU
- 2019.01-2020.12 教育部醫學教育會 委員
- 2015.01-2016.12 教育部醫學教育會 委員
- 2014.08-2019.07 Distinguished Professor and Dean, College of Medicine, National Cheng Kung University
- 2013.08-2014.07 Professor and Dean, College of Medicine, National Cheng Kung University
- 2008.09-2018.05 Distinguished Investigator of National Institute of Cancer Research, NHRI
- 2008.01-2013.07 Director of National Institute of Cancer Research, NHRI
- 2007.08- Attending Physician of Division of hematology/Oncology, NCKUH
- 2007.08-2013.07 Joined Professor, College of Medicine, National Cheng Kung University
- 2006.01-2007.12 Deputy Director of National Institute of Cancer Research, NHRI
- 2004.06-2008 Chairman of Safety and Data Monitoring committee, TCOG
- 2004.04-2008.08 Investigator of NHRI
- 2003.08-2007.07 Adjunct Professor of Internal Medicine, NDMC (部定，教字013198)
- 2003-2005 常務理事，Chinese Oncology Society
- 2001~ Board member of Chinese Oncology Society
- 2000.09-2004.03 Associate investigator of NHRI
- 1999 ~ Board member of Sino-American Cancer Foundation
- 1997-2006 Adjunct Attending physician of Department of Oncology, NTUH
- 1997- Senior Attending physician of NHRI
- 1997-2001 General Secretary of Chinese Oncology Society
- 1997 Chief of Hematology / Oncology, Cheng-Hsien Medical
Center - 1994-2003.07 Associate Professor of internal medicine, NDMC (部定，副字 21234)
- 1994-1996 Board member of Chinese BMT Society
- 1993-1996 Chief of Medical Oncology, Tri-Service General Hospital, National Defense Medical Center
- 1991-1992 Attending physician of Medical Mission in Republic of Central Africa
- 1989-1991 Visiting Scholar of Yale Medical School, Department of Pharmacology
- 1987-1989 Fellow of Medical Oncology Training Program of Institute of Biomedical Science, Academia Sinica
- 1987-1996 Attending Physician of Hematology / Oncology, Tri-Service General Hospital, NDMC
- 1986-1987 Chief resident of Division of Hematology / Oncology,
Department of Internal Medicine, TSGH, NDMC - 1982-1986 Resident of Department of Medicine, TSGH, NDMC
- 1981-1982 Internship training, Tri-Service General Hospital
研究興趣
- Development of anticancer drugs
- Study the mechanisms of anticancer drug resistance
指紋
查看啟用 Jang-Yang Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
在頭頸癌中探討組織蛋白酶S調控溶酶體的分子機制和其中與臨床關聯性之研究( I )
Chang, J.-Y. (PI)
8/1/24 → 7/31/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
在頭頸癌中探討組織蛋白酶S調控溶酶體的分子機制和其中與臨床關聯性之研究(1/3)
Chang, J.-Y. (PI)
8/1/24 → 7/31/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
腫瘤微環境中癌細胞與免疫因子的串擾：頭頸癌的組織蛋白酶S相關調節機制鑑定和治療策略－溶酶體半胱氨酸蛋白酶組織蛋白酶S在頭頸癌腫瘤免疫中的作用：聚焦對IL-7的調節角色和潛在的免疫調節機制(3/3)
Chang, J.-Y. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
探討cathepsin S在奧沙利鉑引起的神經病變的作用角色: 預測和預防周邊神經病變的潛在生物標誌(3/3)
Chang, J.-Y. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
Correction: The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b (Pharmaceutics, (2022), 14, (1511), 10.3390/pharmaceutics14071511)
Lee, Y. Z., Hsu, H. Y., Yang, C. W., Lin, Y. L., Chang, S. Y., Yang, R. B., Liang, J. J., Chao, T. L., Liao, C. C., Kao, H. C., Chang, J. Y., Sytwu, H. K., Chen, C. T. & Lee, S. J., 2月 2023, 於: Pharmaceutics. 15, 2, 342.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy
Tang, Y. C., Chuang, Y. J., Chang, H. H., Juang, S. H., Yen, G. C., Chang, J. Y. & Kuo, C. C., 2023, 於: Journal of Food and Drug Analysis. 31, 3, p. 387-407 21 p., 2.研究成果: 雜誌貢獻 › 回顧型文獻 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death
Lin, C. P., Wu, S. H., Lin, T. Y., Chu, C. H., Lo, L. W., Kuo, C. C., Chang, J. Y., Hsu, S. C., Ko, B. S., Yao, M., Hsiao, J. K., Wang, S. W. & Huang, D. M., 11月 2023, 於: Pharmacological Research. 197, 106945.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition
Hsiao, S. Y., Weng, S. M., Hsiao, J. R., Wu, Y. Y., Wu, J. E., Tung, C. H., Shen, W. L., Sun, S. F., Huang, W. T., Lin, C. Y., Chen, S. H., Hong, T. M., Chen, Y. L. & Chang, J. Y., 12月 2023, 於: Journal of Experimental and Clinical Cancer Research. 42, 1, 40.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取11 引文 斯高帕斯（Scopus） -
Synthesis and Structure–Activity Relationship of Salvinal Derivatives as Potent Microtubule Inhibitors
Chang, C. I., Hsieh, C. C., Wein, Y. S., Kuo, C. C., Chang, C. Y., Lung, J., Cherng, J. Y., Chu, P. C., Chang, J. Y. & Kuo, Y. H., 4月 2023, 於: International journal of molecular sciences. 24, 7, 6386.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取
資料集
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I.-T. (Contributor), Kuo, C.-C. (Contributor), Liou, J.-P. (Creator) & Chang, J.-Y. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
資料集: Dataset